Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01418300

Enrollment

159

Registered

2011-08-17

Start date

2010-08-31

Completion date

2011-12-31

Last updated

2015-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Infected Patients

Brief summary

The purpose of this study is to improve first line Helicobacter pylori eradication rate and to compare the sequential versus conventional triple therapy.

Interventions

DRUGsequential versus triple

sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* peptic ulcer diseae * two test positive rapid urease test, culture, histology

Exclusion criteria

* lactating or pregnant * previous stomach surgery * severe underlying disease

Design outcomes

Primary

Measure	Time frame	Description
the eradication rate by urea breath test	4-6 week later after completion of therapy	to compare the eradication rate (intention-to-treat and per protocol) by urea breath test at least four weeks after treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026